0 5 Nasal nasal JJ 6 9 NK- NK- NNP 10 13 and and CC 14 20 T-cell T-cell NNP 21 30 lymphomas lymphoma NNS 31 36 share share VBP 37 40 the the DT 41 45 same same JJ 46 50 type type NN 51 53 of of IN 54 66 Epstein-Barr epstein-barr JJ 67 72 virus virus NN 73 80 latency latency NN 81 83 as as IN 84 98 nasopharyngeal nasopharyngeal JJ 99 108 carcinoma carcinoma NN 109 112 and and CC 113 120 Hodgkin Hodgkin NNP 120 122 ’s 's POS 123 130 disease disease NN 130 131 . . . 133 138 Nasal nasal JJ 139 148 T/NK-cell T/NK-cell NNP 149 158 lymphomas lymphoma NNS 159 162 can can MD 163 165 be be VB 166 173 further further RBR 174 183 separated separate VBN 184 188 into into IN 189 194 those those DT 195 197 of of IN 198 205 natural natural JJ 206 212 killer killer NN 213 214 ( ( ( 214 216 NK NK NNP 216 217 ) ) ) 218 222 cell cell NN 223 230 lineage lineage NN 231 233 or or CC 234 236 of of IN 237 243 T-cell t-cell NN 244 251 lineage lineage NN 251 252 , , , 253 257 with with IN 258 269 differences difference NNS 270 272 in in IN 273 281 cellular cellular JJ 282 291 phenotype phenotype NN 291 292 , , , 293 299 T-cell t-cell NN 300 308 receptor receptor NN 309 310 ( ( ( 310 313 TcR TcR NNP 313 314 ) ) ) 315 319 gene gene NN 320 333 rearrangement rearrangement NN 334 337 and and CC 338 341 TcR tcr NN 342 352 transcript transcript NN 353 363 expression expression NN 363 364 . . . 365 369 Both both CC 370 373 NK- nk- NN 374 377 and and CC 378 384 T-cell t-cell NN 385 393 subtypes subtype NNS 394 397 are be VBP 398 405 closely closely RB 406 416 associated associate VBN 417 421 with with IN 422 434 Epstein-Barr epstein-barr JJ 435 440 virus virus NN 441 442 ( ( ( 442 445 EBV EBV NNP 445 446 ) ) ) 446 447 . . . 448 450 In in IN 451 455 this this DT 456 461 study study NN 461 462 , , , 463 466 EBV EBV NNP 467 471 gene gene NN 472 482 expression expression NN 483 486 was be VBD 487 497 determined determine VBN 498 500 in in IN 501 503 23 23 CD 504 509 cases case NNS 510 512 of of IN 513 518 nasal nasal JJ 519 527 lymphoma lymphoma NN 528 529 ( ( ( 529 531 NL NL NNP 531 532 ) ) ) 533 535 by by IN 536 538 in in FW 539 543 situ situ FW 544 557 hybridisation hybridisation NN 558 559 ( ( ( 559 562 ISH ISH NNP 562 563 ) ) ) 563 564 , , , 565 572 reverse reverse JJ 573 597 transcriptase-polymerase transcriptase-polymerase NN 598 603 chain chain NN 604 612 reaction reaction NN 613 614 ( ( ( 614 620 RT-PCR RT-PCR NNP 620 621 ) ) ) 622 625 and and CC 626 646 immunohistochemistry immunohistochemistry NN 647 648 ( ( ( 648 650 IH IH NNP 650 651 ) ) ) 651 652 . . . 653 655 Of of IN 656 659 the the DT 660 662 23 23 CD 663 668 cases case NNS 668 669 , , , 670 672 19 19 CD 673 677 were be VBD 678 688 classified classify VBN 689 691 as as IN 692 699 NK-cell NK-cell NNP 700 703 and and CC 704 705 4 4 CD 706 708 as as IN 709 715 T-cell t-cell NN 716 723 tumours tumour NNS 723 724 . . . 725 728 ISH ish NN 729 732 for for IN 733 744 EBV-encoded ebv-encoded JJ 745 750 small small JJ 751 769 non-polyadenylated non-polyadenylated JJ 770 774 RNAs rna NNS 775 781 showed show VBD 782 786 that that IN 787 790 all all DT 791 796 cases case NNS 796 797 , , , 798 805 whether whether IN 806 808 NK NK NNP 809 811 or or CC 812 813 T t NN 813 814 , , , 815 824 harboured harbour VBD 825 828 EBV EBV NNP 829 831 in in IN 832 841 virtually virtually RB 842 845 all all DT 846 852 tumour tumour NN 853 858 cells cell NNS 858 859 . . . 860 866 RT-PCR RT-PCR NNP 867 879 demonstrated demonstrate VBD 880 884 that that IN 885 887 NL NL NNP 888 890 of of IN 891 895 both both DT 896 904 subtypes subtype NNS 905 914 expressed express VBD 915 920 EBNAI EBNAI NNP 921 923 of of IN 924 927 the the DT 928 931 QUK QUK NNP 932 938 splice splice NN 939 946 pattern pattern NN 946 947 , , , 948 951 the the DT 952 958 latent latent JJ 959 967 membrane membrane NN 968 976 proteins protein NNS 976 977 , , , 978 982 LMP1 LMP1 NNP 983 986 and and CC 987 988 2 2 CD 989 992 and and CC 993 996 the the DT 997 1002 BamHI BamHI NNP 1003 1004 A a NN 1005 1014 rightward rightward JJ 1015 1026 transcripts transcript NNS 1027 1029 in in IN 1030 1033 the the DT 1034 1041 absence absence NN 1042 1044 of of IN 1045 1050 EBNA2 ebna2 NN 1051 1056 mRNAs mrna NNS 1056 1057 , , , 1058 1068 compatible compatible JJ 1069 1073 with with IN 1074 1077 the the DT 1078 1085 latency latency NN 1086 1090 type type NN 1091 1093 II ii CD 1094 1101 pattern pattern NN 1101 1102 . . . 1103 1105 In in IN 1106 1114 addition addition NN 1114 1115 , , , 1116 1124 analysis analysis NN 1125 1127 of of IN 1128 1131 EBV EBV NNP 1132 1139 protein protein NN 1140 1150 expression expression NN 1151 1153 by by IN 1154 1156 IH IH NNP 1157 1165 revealed reveal VBD 1166 1167 a a DT 1168 1181 heterogeneous heterogeneous JJ 1182 1189 pattern pattern NN 1190 1192 of of IN 1193 1196 EBV EBV NNP 1197 1201 gene gene NN 1202 1212 expression expression NN 1213 1215 at at IN 1216 1219 the the DT 1220 1231 single-cell single-cell JJ 1232 1237 level level NN 1238 1248 consisting consist VBG 1249 1251 of of IN 1252 1256 both both CC 1257 1262 LMP1+ lmp1+ NN 1263 1266 and and CC 1267 1272 LMP1- lmp1- NN 1273 1279 tumour tumour NN 1280 1285 cells cell NNS 1285 1286 , , , 1287 1297 suggesting suggest VBG 1298 1299 a a DT 1300 1307 mixture mixture NN 1308 1310 of of IN 1311 1318 latency latency NN 1319 1320 I i CD 1321 1324 and and CC 1325 1327 II ii CD 1327 1328 . . . 1329 1337 Although although IN 1338 1339 2 2 CD 1340 1345 early early JJ 1346 1351 lytic lytic JJ 1352 1363 transcripts transcript NNS 1363 1364 , , , 1365 1370 BZLF1 BZLF1 NNP 1371 1374 and and CC 1375 1380 BHRF1 BHRF1 NNP 1380 1381 , , , 1382 1386 were be VBD 1387 1391 also also RB 1392 1400 detected detect VBN 1401 1403 in in IN 1404 1406 13 13 CD 1407 1410 and and CC 1411 1413 10 10 CD 1414 1419 cases case NNS 1419 1420 , , , 1421 1433 respectively respectively RB 1433 1434 , , , 1435 1438 the the DT 1439 1443 lack lack NN 1444 1446 of of IN 1447 1452 ZEBRA ZEBRA NNP 1453 1461 staining staining NN 1462 1464 in in IN 1465 1468 any any DT 1469 1473 case case NN 1474 1483 indicates indicate VBZ 1484 1488 that that IN 1489 1494 these these DT 1495 1500 lytic lytic JJ 1501 1512 transcripts transcript NNS 1513 1516 are be VBP 1517 1521 most most RBS 1522 1528 likely likely RB 1529 1538 expressed express VBN 1539 1541 by by IN 1542 1546 rare rare JJ 1547 1552 cells cell NNS 1553 1555 in in IN 1556 1559 the the DT 1560 1568 biopsies biopsy NNS 1569 1577 entering enter VBG 1578 1583 lytic lytic JJ 1584 1589 cycle cycle NN 1589 1590 . . . 1591 1594 The the DT 1595 1600 viral viral JJ 1601 1616 transcriptional transcriptional JJ 1617 1624 pattern pattern NN 1625 1632 similar similar JJ 1633 1635 to to TO 1636 1640 that that DT 1641 1643 of of IN 1644 1658 nasopharyngeal nasopharyngeal JJ 1659 1668 carcinoma carcinoma NN 1669 1672 and and CC 1673 1680 Hodgkin Hodgkin NNP 1680 1682 ’s 's POS 1683 1690 disease disease NN 1691 1699 suggests suggest VBZ 1700 1704 that that IN 1705 1708 EBV EBV NNP 1709 1712 can can MD 1713 1720 exploit exploit VB 1721 1727 common common JJ 1728 1738 regulatory regulatory JJ 1739 1749 mechanisms mechanism NNS 1750 1753 for for IN 1754 1758 gene gene NN 1759 1772 transcription transcription NN 1773 1775 in in IN 1776 1783 diverse diverse JJ 1784 1788 host host NN 1789 1793 cell cell NN 1794 1799 types type NNS 1799 1800 . . . 1801 1816 Down-regulation down-regulation NN 1817 1819 of of IN 1820 1831 immunogenic immunogenic JJ 1832 1840 proteins protein NNS 1841 1842 ( ( ( 1842 1853 EBNA2-EBNA6 EBNA2-EBNA6 NNP 1853 1854 ) ) ) 1855 1857 in in IN 1858 1863 nasal nasal JJ 1864 1872 lymphoma lymphoma NN 1873 1876 may may MD 1877 1883 enable enable VB 1884 1890 tumour tumour NN 1891 1896 cells cell NNS 1897 1899 to to TO 1900 1905 evade evade VB 1906 1910 host host NN 1911 1920 cytotoxic cytotoxic JJ 1921 1927 T-cell t-cell NN 1928 1940 surveillance surveillance NN 1940 1941 . . .